FDA head suspects economic motives behind tainted heparin

04/15/2008 | Wall Street Journal (free content), The · Bloomberg11

FDA Commissioner Andrew von Eschenbach told a Senate Appropriations subcommittee that the agency believes batches of Baxter International's blood thinner heparin may have been contaminated "by virtue of economic fraud." After the hearing, however, von Eschenbach told reporters that the agency had no proof the contamination was committed on purpose.

View Full Article in:

Wall Street Journal (free content), The · Bloomberg11

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
PacificSource
Boise, ID